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The study was carried out to investigate whether an interaction between albendazole and ivermectin 
could lead to enhanced central nervous system (CNS) toxicity. Ivermectin (0.4mg/kg body weight (b.w)) 
and/or albendazole (15mg/kg b.w) were daily and orally administered to albino rats for 14 days. Activities of 
acid phosphatase (ACP), alkaline phosphatase (ALP), catalase (CAT), Na+-K+ ATPase, Ca2+-Mg2+ ATPase and 
malondialdehyde (MDA) level which are considered essential to correct functioning of the brain were 
determined. The co-administration of the two drugs si nificantly caused reduction (p<0.05) in the activities of 
brain ACP, ALP, Na+-K+ ATPase and Ca2+-Mg2+ ATPase with corresponding increase in the serum. Separate 
administration of ivermectin or albendazole did notshow any significant changes (p>0.05) in the activity of 
these enzymes. These suggest that in the presence of albendazole, ivermectin is able to reach the CNS and 
impair its function through neurochemical changes. Al o, co-administration of ivermectin and albendazole led 
to a significant increase (p<0.05) in brain CAT activity as well as serum and brain MDA concentrations. This 
may be an indication that the drugs have other mechanisms of action, such as increasing oxidative damage in 
the CNS. Overall, these findings suggest that both drugs exert additive effect when co-administered. 
© 2012 International Formulae Group. All rights reserved. 
 




Brain is a vital organ of the body whose 
function controls the activities of the cellular 
system. It consists of three parts viz. 
forebrain, midbrain, and hindbrain. It is 
involved in sensory perception, motor control, 
memory association, thought and personality, 
regulating temperatures, water metabolism, 
blood sugar level, productive cycle, hunger, 
thirst, anger and pleasure (Cicerone et al, 
2005), and several forms of reflex actions. 
Due to the complexity of its functions, the 
brain receives some 15% of the total cardiac 
output and accounts for about 20% of the total 
oxygen consumption of the body at rest 
(Alavijeh et al, 2005). The high oxygen 
utilization by the brain during metabolism 
increases its susceptibility to oxygen free 
radicals which is the major mode of action of 
neurotoxicant. However, the brain regulates 
transport of materials in and out through the 
action of blood-brain barrier which is 
composed of specialized endothelial cells that 
prevent various substances from entering the 
brain except those that are either small or 
lipophilic (Rubin and Staddon, 1999) thereby 
reducing accumulation of toxic materials in 
the brain.  
Ivermectin and albendazole are 
synthetic drugs used for the treatment of 





Lymphatic filariasis (Elephantiasis) and 
Onchocerciasis (river blindness) respectively. 
Both diseases are major public health 
problems in several tropical countries (Ottesen 
and Ramachandran, 1995). An estimated 120 
million people in more than 80 endemic 
countries are infected with Lymphatic 
filariasis (Molyneux et al., 2003) and 50 
million individuals remain at risk with 17.7 
million infected with Onchocerca volvulus 
predominantly in 22 sub-Saharan African 
countries. The strategy that has been shown to 
be most effective is the treatment of affected 
populations with the drug ivermectin - a white 
or slightly yellow crystalline powder (Chabala 
et al., 1980). However, report of resistance to 
ivermectin in nematodes is becoming 
increasingly common (Richard, 1994; 
Sangster, 1996). In view of this and the co-
endemic nature of the two diseases, clinical 
trials of ivermectin and albendazole 
combination commenced in some African 
countries like Ghana (Awadzi et al., 2003). 
The advantageous pharmacologic action of 
this combination therapy is that while 
ivermectin is only microfilaricidal (Goa et al., 
1991) albendazole is toxic to all intra–uterine 
stages (Awadzi et al., 1995). Although, this 
regimen has been tried in many countries with 
reports of high efficacy in the treatment of 
onchocerciasis and lymphatic filariasis (Ismail 
et al., 1998; Awadzi et al., 2003), their effect 
on various metabolic processes, tissues and 
cellular systems of the mass human 
populations receiving these drugs is yet to be 
clarified. This study is thus aimed at 
elucidating the toxic effect of the combination 
therapy on the cellular integrity of the brain of 
wistar rats. 
 
MATERIALS AND METHODS 
Materials 
Experimental animals 
A total of 20 male albino rats (Rattus 
novergicus) of average weight 157.50 g +2.50 
g were obtained from the Animal Holding 
Unit of the Department of Biochemistry, 
University of Ilorin, Ilorin, Nigeria. The rats 
were maintained on normal rat chow and 
water ad libitum and were housed in wooden 
cages. Animal husbandry and experimentation 
were consistent with the Guiding Principles in 
the Use of Animals in Toxicology (Derelanko, 
2000).  
Drugs and reagents 
 Ivermectin and albendazole were 
products of Merck and Co. England and 
Glaxo Smithkline Beecham, Netherlands 
respectively. All reagents used were of 
analytical grade and were prepared in all-glass 
distilled water. The reagents were stored in 
clean, air tight reagent bottles. 
 
Methods 
Animal grouping and drug administration 
The rats were randomly divided into 
four groups of five rats each. Group I (control) 
received an appropriate volume of distilled 
water. Group II (Iver) received a human 
therapeutic dose of 0.4 mg/kg body weight 
(b.w.) ivermectin; Group III (Alb) received a 
human therapeutic dose of 15 mg/kg body 
weight albendazole while group IV (Iver + 
Alb) received a dose of 0.4 mg/kg body 
weight ivermectin co-administered with 15 
mg/kg body weight albendazole. The 
administration was done orally on a daily 
basis for fourteen (14) days at 24 h interval (at 
9.00a.m). This duration was based on the 
clinical trial conducted by Ismail et al. (1998) 
to evaluate the potency of the combination 
therapy. The animals were sacrificed 24 h 
after the fourteenth day administration. 
Preparation of serum and brain homogenate 
At the end of the experimental period, 
approximately 5 ml of venous blood was 
collected from each of the experimental 
animals according to the method of 
Narayanan et al. (1984) The serum was 
prepared by centrifuging the blood samples at 
3000 rpm for 5 min (Ogbu and Okechukwu, 
2001) and serum collected with a Pasteur 
Pipette. Immediately after the collection of 
blood, the brain was removed and transferred 
into a well labelled container of ice-cold 0.25 
M sucrose solution (1:5 w/v) and 





homogenized. The homogenates were kept 
frozen overnight to ensure maximum release 
of the enzymes before being used for the 
various biochemical assays (Adebayo et al., 
2003).  
 
Assay of enzyme activities and lipid 
peroxidation 
Acid phosphatase activity was assayed 
using the method of Armstrong (1964). The 
method of Bessey et al. (1946) as modified by 
Wright et al. (1974) was employed for the 
assay of alkaline phosphatase activity. 
ATPase activities were assayed using the 
method of Ronner et al. (1977) and catalase 
by the method of Sinha (1971). Determination 
of malondialdehyde level was done by the 
method of Varshney and Kale (1990). Protein 
content of the homogenate and serum were 
determined using the Biuret method (Gornall 
et al., 1949). 
 
Statistical analysis 
All data are presented as mean ± 
standard deviation. Statistical analyses were 
carried out using Duncan Multiple Range test 
(Montgomery, 1976). In all cases, probability 
level of 95% was taken as significant. 
 
RESULTS 
Figure 1 shows the effect of 
administration of ivermectin and /or 
albendazole for 14 days on rat brain-body 
weight ratios. Combined administration of 
both drugs significantly reduced (p<0.05) 
brain-body weight ratios of rats. There was no 
significant change in this parameter in rats 
administered separately with ivermectin or 
albendazole when compared with controls.  
Figure 2 shows the activity of ALP in 
brain of rats following the administration of 
ivermectin, albendazole and their combination 
for 14 days. The serum ALP activity was 
significantly increased (P<0.05) in all 
treatment groups when compared with the 
controls. There existed no significant 
difference (P>0.05) in the brain ALP activity 
of rats administered separately with 
ivermectin or albendazole when compared 
with the control. However, about two folds 
reduction in activity was observed following 
co-administration of both drugs for 14 days 
when compared with control.  
Figure 3 presents the effects of both 
separate and combined administration of 
ivermectin and albendazole for 14 days on the 
activity of acid phosphatase (ACP) of rat 
brain. The serum acid phosphatase activity 
increased significantly (P<0.05) following 
combined administration of ivermectin and 
albendazole while there was no significant 
differences (P>0.05) when each drug was 
seperately administered to rats compared with 
control. There was no significant difference 
(P>0.05) in the brain ACP activity of rats 
administered ivermectin  and albendazole 
seperately while in rats administered 
combined invermectin and albendazole, there 
was a significant  increase (P<0.05) in activity 
when compared with control. 
Combined administration of ivermectin 
and albendazole for 14 days caused significant 
(P<0.05) drop in brain Na+-K+ and Ca2+-Mg2+ 
ATPase activities (Figures 4 and 5). However, 
no significant changes (p>0.05) were 
observed following separate administration 
for the same period. 
Separate administration of ivermectin and 
albendazole did not affect (P>0.05) brain 
catalase activity (Figure 6). However their co–
administration led to a significant increase 
(P<0.05) in the enzyme activity of brain when 
compared with control. 
Neither of the drugs caused any 
significant change (P>0.05) in 
the concentration of MDA in the serum and 
brain when compared with controls following 
14 days administration (Figure 7). However, 
co–administration of ivermectin with 
albendazole for 14 days caused a significant 
elevation (P<0.05) in both serum and brain 
malondialdelhyde levels. 






Figure 1: Brain-body weight ratio of rats following the daily administration of ivermectin 
and/or albendazole for fourteen days. 
Values are means (n = 5) + S.D (bars with different superscripts are significantly different at P<0.05).  
Iver = Ivermectin; Alb = Albendazole. 























































Figure 2: Specific activities of alkaline phosphatase in rat brain following the daily administration 
of ivermectin and/or albendazole for fourteen days. 
Values are means (n=5) + S.D (bars with different superscripts are significantly different at P<0.05).    


















































































Figure 3: Specific activitivies of acid phosphatase in rat brain following the daily administration 
of ivermectin   and/or albendazole for fourteen days. 
Values are means (n=5) + S.D (bars with different superscripts are significantly different at P<0.05).     




Figure 4: Specific activities of rat brain Na+-K+ ATPase following the daily administration of 
ivermectin and/or albendazole for fourteen days. 
Values are means (n=5) + S.D (bars with different superscripts are significantly different at P<0.05).   









































Figure 5: Specific activities of rat brain Ca2+-Mg2+ ATPase following the daily administration of 
ivermectin and/or albendazole for fourteen days. 
Values are means (n=5) + S.D (bars with different superscripts are significantly different at P<0.05).  































Figure 6: Effects of ivermectin and/or albendazole on rat brain catalase activities following 
fourteen days of drug administration. 
Values are means (n=5) + S.D (bars with different superscripts are significantly different at P<0.05). 





















































































Figure 7: Effects of ivermectin and/or albendazole on malondialdehyde (MDA) concentration1 in 
rat brain followingr fourteen  days of drug administration. 





Organ/body weight ratios are normally 
investigated to determine change in size of the 
organ relative to the body (Bailey et al., 
2004). High Organ to body weight ratio has 
been associated to inflammation while 
otherwise is necrosis. Xenobiotics (including 
drugs) have been reported to induce 
inflammatory responses (Omiecinski, 2011) 
disrupting respiration and affecting energy 
production. This may result in dependence of 
the brain cells on anaerobic respiration to 
generate energy. The eventual accumulation 
of the product of this process- lactic acid in 
brain cells may lead to cell damage as a result 
of lactic acidosis with consequent 
inflammation.  Efflux mechanism at the 
blood–brain barrier is a limiting factor in the 
penetration of drugs. Drugs including 
ivermectin and albendazole are actively 
transported out of brain, thus limiting the 
concentration of these compounds in the brain 
(Taylor and Yan, 2002). The significant 
decrease in the brain/body weight ratio of rats 
administered combined ivermectin and 
albendazole, suggests appreciable 
accumulation of ivermectin in the brain thus 
causing cell death. Ivermectin is known to be 
neurotoxic because of its action on GABA 
receptors (Leo et al., 1996). Both ivermectin 
and albendazole have been reported as 
cosubstrates of cytochrome P450 (CY3A4) 
(Edwards, 2003). However it has also been 
proposed that albendazole may be substrate to 
p-glycoprotein (Redondo et al., 1999). 
Therefore, since p-glycoprotein may have 
higher affinity for albendazole, it may in the 
presence of ivermectin mediate the efflux of 
albendazole allowing ivermectin to 
accumulate appreciably in the brain. 
The significant increase in serum ALP activity 
of all the treatment groups following 14 days 
administration (P<0.05) when compared with 
the control is suggestive of a possible damage 
to tissue cell plasma membrane by the 
administration of the drugs either singly or in 
combination, thus leading to leakage of 
membrane components into the extracellular 
fluid (Akanji et al., 1993). This is further 
supported by significant reduction in brain 





ALP activity following the co-administration 
of ivermectin with albendazole for 14 days. 
This effect may be attributed to the role of p-
glycoprotein of blood brain barrier (BBB) and 
the fact that albendazole has been proposed to 
be a substrate to p-glycoprotein (Redondo et 
al., 1999). It may be possible that p-
glycoprotein has higher affinity for 
albendazole and in the presence of ivermectin 
mediated the efflux of albendazole thereby 
allowing ivermectin to accumulate 
appreciably in the brain to exert its neurotoxic 
effects on the brain cells, one of which is 
membrane derangement and hence the 
observed loss of ALP activity. 
Acid phosphatase is an enzyme of the 
lysosomal membrane (Zhang et al., 2009). 
Acid phosphatase was chosen for assay on the 
basis of its specificity for lysosomal 
membrane. Its activity before and after 
exposure to insult with chemical compounds 
(in this case ivermectin and/or albendazole) 
gives a picture of the sequence of cell damage 
if any. Alteration in acid phosphatase activity 
will thus explain the suspected effects of these 
drugs on lysosomes (Zhang et al., 2009). The 
increase in ACP activity observed following 
combined administration of the drug could be 
a consequence of de novo synthesis induction 
by accumulation of ivermectin in the brain. 
Another possible explanation is the release of 
the enzyme from the brain lysosomal 
membrane, an indication of tissue damage. 
Na+-K+ ATPase is a membrane bound 
enzyme invoved in maintaining potential 
difference across the plasma membrane and 
also mediates transport of several other 
molecules into the cells. The brain Na+-
K+ ATPase activity was significantly reduced 
in the combination group. This may be 
ascribed to the modulatory effect of 
albendazole in potentiating the neurotoxic 
effect of ivermectin by competitively 
preventing its efflux by p-glycoprotein while 
albendazole gets pumped out of the brain. The 
reduced activity observed could be attributed 
to the binding of the drug to various subunits 
essential for the activity of the enzyme 
possibly via cysteine residues, as reported in 
the interaction of ivermectin with cytochrome 
P450 CY3A (Beers and Berkow, 1999; Rossi, 
2000) which may reduce the enzyme activity. 
Ca2+ plays a very important role as second 
messenger, effecting brain signals. Its gradient 
is maintained by several of its transporter 
across the cellular membrane. The significant 
reduction in activity of Ca2+-Mg2+ ATPase 
following ivermectin, and albendazole 
administration may be attributed to membrane 
derangement or inhibition of the enzyme by 
the drugs. Ahern et al. (1999) reported that 
ivermectin increased Ca2+ release from 
sarcosplasmic reticulum vesicles and from 
endosplasmic reticulum by inhibiting Ca2+ 
uptake by Ca2+ -Mg2+ ATPase.  
Exposure to xenobiotics results into 
many complex processes which can be 
evaluated by antioxidant enzyme activity as 
well as by lipid peroxidation measures 
(Romeo et al., 2000). Increase in catalase 
activity could be attributed to compromise of 
the tissue xenobiotic protective 
biotransformation mechanism which may 
have resulted from accumulation of 
ivermectin in the brain mediated by 
albendazole thus leading to the production of 
reactive oxygen species and concomittant 
increased catalase activity to cope with these. 
Lipid peroxidation is assessed by 
maximal rate of malondialdehyde formation 
(Chield et al., 1999). The integrity of cells 
could be assessed by evaluating the 
malondialdehyde level. Usually, the level is 
elevated under conditions such as oxidative 
stress where reactive oxygen group could 
react with unsaturated fat and increase 
malondialdehyde formation. In the brain, 
malondialdehyde levels can be used to 
measure various diseased conditions. Weigand 
et al. (1999) investigated cerebral formation of 
malondialdehyde as an index of lipid 
peroxidation in relation to different sources of 
reactive oxygen species in patients undergoing 
carotid endarterectomy. It has been proposed 





to be one of the major mechanisms of 
secondary damage in traumatic brain injury. 
The brain is particularly prone to oxidative 
injury because the membrane lipids are 
essentially rich in polyunsaturated fatty acid 
(Halliwell and Gutteridge, 1989). Increased 
serum MDA levels have been found in 
patients with cancer (Huang et al., 1999). The 
increase in MDA level observed in this study 
suggests that the antifilarials are capable of 
inducing oxidative stress which is in 
agreement with the report of Yarsan et 
al.(2002) that albendazole caused increased 




The current study suggested that 
albendazole may mediate neurotoxic effect of 
ivermectin during combined administration 
for the treatment of filarial diseases. This 
study however, gives way to further study for 
the determination of kinetic parameters as a 
measure of affinity of p- glycoprotein for 
ivermectin and albendazole.  
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